Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bayer To Establish Manufacturing Capacity in Germany | Contract Pharma

What are you searching for?

Sign in
Breaking News

Bayer To Establish Manufacturing Capacity in Germany

To support factor VIII (rFVIII) hemophilia products in Phase III development

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bayer HealthCare is investing more than €500 million to establish manufacturing capacity for recombinant factor VIII (rFVIII) hemophilia products that are currently in development at its sites in Wuppertal and Leverkusen, Germany. The company’s two investigational therapies for hemophilia A are currently in Phase III development. Bayer’s approved hemophilia A product is manufactured exclusively in Berkeley, CA. The additional supply source in Germany will help prepare for production of the new therapies upon approval.  

“This investment will be one of the largest in the history of Bayer HealthCare and reflects our strong commitment in the hemophilia field,” said Dr. Olivier Brandicourt, chief executive officer of Bayer HealthCare.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics